19 March 2010
Further to our 5 March post, in the first successful Vioxx class action anywhere in the world, the Federal Court has found that Vioxx doubled the risk of heart attack in patients.
The Court found that Vioxx was not ‘of merchantable quality’ and was not fit for the purpose of treating arthritis. While dismissing claims that Merck had been negligent, the Court was satisfied that that there had been a breach of the Trade Practices Act. Click here to read more.